Roche NimbleGen and BioDiscovery Form Strategic Alliance to Enhance CGH Microarrays, Software and Services
News Jun 04, 2008
Roche NimbleGen Inc., a company of Roche Applied Science, announced that it has formed a strategic alliance with BioDiscovery, Inc. to offer complete solutions to comparative genomic hybridization (CGH) microarray customers.
The high-density 2.1 million probe (HD2) arrays of Roche NimbleGen combined with proprietary software, Nexus Copy Number, of BioDiscovery bring power and ease in whole-genome CGH analysis.
As part of this alliance Roche NimbleGen and BioDiscovery will co-market and co-promote their products and services to scientists worldwide. The companies also plan to present data generated from NimbleGen CGH arrays using Nexus software of BioDiscovery to the research community through a series of seminars.
"This alliance with BioDiscovery will enable Roche NimbleGen to significantly enhance the customer experience by providing complete data analysis solutions for our customers using NimbleGen arrays for CGH analysis. At the same time we are excited about the opportunity to develop a strong business relationship with BioDiscovery in offering complete solutions to our customers in genomics and life sciences," said Srini Ramachandra, Senior Director for Software Marketing at Roche NimbleGen.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019